In contrast, there was a significant relationship between high SLCO1B3 expression and better survival outcome after excluding breast cancer patients without adjuvant treatments (e.g.: adjuvant chemotherapy and endocrine therapy). This evidence concerns the gene SLCO1B3 and breast carcinoma.